N/A N=408 Prostate Cancer Screening Trial Using Imaging
Prostate Neoplasm
Primary: The Proportion of Men With a Positive MRI Defined by a Score of 3 or Greater — 17.7 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=812 Community Interventions in Non-medical Settings to Increase Informed Decision Making for Prostate Cancer Screening
Prostate Cancer
Primary: Percentage of Patients Who Were Ready to Make a Decision or Were Undecided — 134; 90; 144; 125 Participants
N/A N=161 Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men
Prostate Cancer
Primary: Shared Decision-making — 12.54; 12.15 Units on a scale — p=0.8388
N/A N=1 Prostate Cancer Screening in Men With Germline BRCA2 Mutations
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Phase 4 N=383 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
Prostate Cancer
Primary: Pre/Post Ratio PSA Area Under the Curve (AUC) — 0.57; 0.61 Ratio
Phase 4 N=1,658 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
Prostatic Hyperplasia
Primary: Number of Men With Confirmed Diagnosis of BPH — 386; 437 Participants
N/A N=48 Prostate Cancer Detection Screening MRI Protocol
Prostate Cancer
Primary: Number of Participants With Any Grade or High Grade (Gleason Score 7 or Higher) Prostate Cancer as Measured by Histopathology — 11; 8 Participants
Phase 2 N=80 Prostvac in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer
Primary: Tumor Growth Rate as Measured by Prostate-specific Antigen (PSA) Rise After 6 Months When PROSTVAC is Initiated Compared to a Group on Surveillance for 6 Months…
N/A N=146 Trial of Community Health Worker-led Decision Coaching
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Screening Rates — 77.8; 76.7 Percentage of participants
N/A N=50 Improving Germline Testing in At-Risk Patients With Prostate Cancer
Prostate Cancer
Primary: Number of Participants Agreeing to Proceed With Germline Testing Among Those Approached With the Educational Intervention. — 41 Participants
N/A N=130 Evaluation of Diagnostic Value of 3-T Magnetic Resonance Imaging (MRI) in Suspected Prostate Cancer
Prostatic Neoplasms
Primary: Number of Prostate Cancer Diagnoses in MRI and no MRI Groups — 34; 34 participants
N/A N=35 Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study
Prostate Cancer
Primary: Feasibility - Recruitment — 39 Participants
N/A N=24 Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy
Prostate Cancer · Magnetic Resonance Imaging · Target Lesion
Primary: Number of Participants With Clinically Significant Prostate Cancer — 6; 6 Participants
Phase 2 N=21 Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA
Prostate Cancer
Primary: PSA Response, as Defined by ≥ 50% Decrease in PSA From Baseline — 1 Participants
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
N/A N=112 Streamlined Genetic Testing in Prostate Cancer
Prostate Cancer
Primary: Number of Participants Completing Genetic Testing — 22; 15; 31; 39 Participants — p=0.14
N/A N=11,314 Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors
Cancer of Prostate · Cancer of the Prostate · Prostate Cancer
Primary: Overall Survival — 8.7; 8.8; 8.6; 9.0 years
N/A N=10 A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine
Prostate Cancer
Primary: Number of Participants With Antigen-specific Interferon- Secretion as Measured by Enzyme-linked Immunospot (ELISPOT) Assay — 4 participants
Phase 2 N=154 PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Primary: Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies — 12.2; -6.9 number of positive cells per mm^2
N/A N=101 A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer
Prostate Cancer
Primary: MP-erMRI Classification Sensitivity — 0.875 proportion of true positives
N/A N=239 Educational Intervention in Increasing Knowledge About Prostate Cancer in High-Risk Neighborhoods
Prostate
Primary: Change in Prostate Cancer Knowledge as Measured by the Decisional Conflict Scale — 80; 70 score on a scale
N/A N=507 Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result
Prostatic Neoplasms
Primary: Association of PCA3 Score With Prostate Biopsy Outcome (PCA3 Score Using Cutoff of 25.) — 466; 102; 364; 235 participants
Phase 2 N=13 Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer
Prostate Cancer
Primary: PET Detection of Primary Prostate Cancer — 6; 7 Participants
Phase 2 N=36 PSMA-PET for Biopsy and Treatment Guidance in Primary Prostate Cancer
Prostate Cancer
Primary: Diagnostic Accuracy of PSMA PET — 100; 74 percentage
Phase 3 N=163 68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Metastatic Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Patients Reporting Adverse Reactions — 0 Participants
Phase 1 N=41 A Pilot Study of Vaccination With Epitope-Enhanced TARP Peptide and TARP Peptide-Pulsed Dendritic Cells in the Treatment of Stage D0 Prostate Cancer
Prostate Specific Antigens · Prostate Neoplasms
Primary: Number of Participants With a Positive Immune Response Following Vaccination Determined by Interferon (IFN) Gamma Enzyme-linked Immunosorbent Spot (ELISpot) — 12; 10…
N/A N=25 Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA
Prostate Cancer
Primary: Prostate Cancer Detection Within the Prostate Gland by Copper Cu 64 TP3805 PET — 25 Participants
N/A N=90 Discussing Stopping Cancer Screening and Prognosis With Older Adults
Cancer Screening
Primary: Change in Intentions to be Screened for Colorectal Cancer. — 2.5 score on a scale — p=<0.001
N/A N=480 Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection
Prostate Cancer Detection
Primary: Assesment of Serum Zinc/PSA Ratio in Patients With Prostate Cancer and Benign Prostatic Diseases — 150.8; 239.6 ratio
Phase 2 N=51 The Role of 68Ga-PSMA-11 PET (Prostate Specific Membrane Antigen) in Surgery Guidance in Prostate Cancer
Prostate Cancer
Primary: Sensitivity of PSMA-PET and MRI Imaging Preoperatively for Predicting Extra-prostatic Extension — 86; 57 percentage — p=<0.05